Caption Management LLC Decreases Stake in Organon & Co. $OGN

Key Points

• Caption Management LLC sold 28,131 shares of Organon & Co., reducing its holdings by 60.9% during the 1st quarter, leaving it with 18,058 shares valued at approximately $269,000.
• Several institutional investors, including Brooklyn Investment Group and PARK CIRCLE Co., significantly increased their positions in Organon, showcasing a growing interest in the stock.
• Organon & Co. reported a quarterly EPS of $1.00, surpassing expectations and projecting an annual earnings per share forecast of 3.68 for the current year.

Caption Management LLC lessened its holdings in Organon & Co. (NYSE:OGN - Free Report) by 60.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,058 shares of the company's stock after selling 28,131 shares during the quarter. Caption Management LLC's holdings in Organon & Co. were worth $269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Hsbc Holdings PLC grew its stake in shares of Organon & Co. by 13.9% during the 4th quarter. Hsbc Holdings PLC now owns 13,922 shares of the company's stock worth $208,000 after acquiring an additional 1,703 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Organon & Co. by 9.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 178,292 shares of the company's stock valued at $2,661,000 after buying an additional 15,064 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Organon & Co. by 17.9% during the 4th quarter. Northern Trust Corp now owns 1,914,115 shares of the company's stock valued at $28,559,000 after buying an additional 290,134 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its position in Organon & Co. by 195.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 63,669 shares of the company's stock worth $950,000 after acquiring an additional 42,103 shares during the last quarter. Finally, AXA S.A. grew its position in Organon & Co. by 3.7% during the 4th quarter. AXA S.A. now owns 249,601 shares of the company's stock worth $3,724,000 after acquiring an additional 8,936 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Organon & Co. Stock Up 7.1%

Shares of OGN stock traded up $0.69 during mid-day trading on Friday, hitting $10.37. The company's stock had a trading volume of 4,651,315 shares, compared to its average volume of 3,674,159. Organon & Co. has a 52-week low of $8.01 and a 52-week high of $21.25. The business has a 50-day moving average price of $9.59 and a 200 day moving average price of $11.03. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 3.85, a PEG ratio of 0.95 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The firm had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.55 billion. During the same quarter in the previous year, the business earned $1.12 earnings per share. The company's revenue was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. Research analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 11th. Investors of record on Friday, August 15th will be issued a $0.02 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.08 annualized dividend and a dividend yield of 0.8%. Organon & Co.'s payout ratio is presently 2.97%.

Wall Street Analysts Forecast Growth

OGN has been the topic of several recent research reports. Piper Sandler reduced their price target on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.